Alkermes To Spin Out Oncology Business, Says Inflation Reduction Act Boosts Its Value
Company Raised CNS Product Revenue Guidance
Executive Summary
After a year of strong commercial performance for Lybalvi and with IL-2 drug nemvaleukin in registration-enabling studies, Alkermes is ready to separate its neuroscience and oncology businesses.
You may also be interested in...
Mural Oncology Primed For IL-2 Readouts Next Year
The company, which Alkermes spun out last year, is now positioned as a pure-play oncology specialist with a focus on cytokines.
Alkermes Ready To More Aggressively Pursue Deals After Oncology Spin-Out
After Alkermes spun out its oncology assets into a separate public entity so the company could focus exclusively on neuroscience, CEO Richard Pops said it will look externally to build its pipeline.
Teva Settles On US Vivitrol Despite Conclusion Of Patent-Litigation Trial
Teva potentially was only a matter of days away from hearing a decision in its patent litigation battle over Vivitrol (naltrexone) long-acting injectable, but has instead put pen to paper on a settlement deal.